| Wang, Zheng |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
| Recruiting | 2 | 30 | RoW | Niraparib | Tianjin Huanhu Hospital | Recurrent Glioblastoma | 01/22 | 01/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT02802124: Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma |
|
|
| Terminated | N/A | 30 | RoW | carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor adjacent to GI | Shanghai Proton and Heavy Ion Center | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
NCT05229133: Efficacy and Safety of CLEAR in Myopia and Astigmatism in Chinese Population |
|
|
| Recruiting | N/A | 215 | RoW | CLEAR, Corneal lenticule extraction for advanced refractive correction | Ziemer Ophthalmic Systems AG, Tigermed Consulting Co., Ltd | Myopic Astigmatism | 03/23 | 03/23 | | |
NCT03573791: Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer |
|
|
| Recruiting | N/A | 152 | RoW | | Wuhan Union Hospital, China | Rectal Cancer, Cancer of Rectum, Cancer of the Rectum, Neoplasms, Rectal, Rectal Tumors, Rectum Cancer, Rectum Neoplasms | 05/25 | 05/26 | | |
| Recruiting | N/A | 5000 | RoW | Blood test | Wuhan Union Hospital, China | Neoplasms, Cancer | 11/24 | 12/24 | | |
| Recruiting | N/A | 48 | RoW | Carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Pancreatic Cancer Non-resectable | 12/25 | 12/26 | | |
| Not yet recruiting | N/A | 100 | RoW | Molecular Profiling & drug testing in tumor organoids and PDXs | Wuhan Union Hospital, China | Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | 07/26 | 07/26 | | |
